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REVIEW
Efflux pump inhibitors as a promising adjunct therapy against drug resistant
tuberculosis: a new strategy to revisit mycobacterial targets and repurpose old
drugs
Liliana Rodrigues, Pedro Cravo and Miguel Viveiros
Global Health and Tropical Medicine, GHTM, Instituto de Higiene e Medicina Tropical, IHMT, Universidade Nova de Lisboa, UNL, Lisboa, Portugal
ABSTRACT
Introduction: In 2018, an estimated 377,000 people developed multidrug-resistant tuberculosis (MDR-
TB), urging for new effective treatments. In the last years, it has been accepted that efflux pumps play
an important role in the evolution of drug resistance. Strategies are required to mitigate the conse-
quences of the activity of efflux pumps.
Areas covered: Based upon the literature available in PubMed, up to February 2020, on the diversity of
efflux pumps in Mycobacterium tuberculosis and their association with drug resistance, studies that
identified efflux inhibitors and their effect on restoring the activity of antimicrobials subjected to efflux
are reviewed. These support a new strategy for the development of anti-TB drugs, including efflux
inhibitors, using in silico drug repurposing.
Expert opinion: The current literature highlights the contribution of efflux pumps in drug resistance in
M. tuberculosis and that efflux inhibitors may help to ensure the effectiveness of anti-TB drugs. However,
despite the usefulness of efflux inhibitors in in vitro studies, in most cases their application in vivo is
restricted due to toxicity. In a time when new drugs are needed to fight MDR-TB and extensively drug-
resistant TB, cost-effective strategies to identify safer efflux inhibitors should be implemented in drug
discovery programs.
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Tuberculosis (TB) remains a serious Public Health problem world-
wide, causing millions of deaths per year and it is estimated that
one-third of the world population is latently infected [1]. Recently,
the World Health Organization (WHO) has launched the ‘End TB’
strategy, which aims to reduce TB deaths by 95% and to cut new
cases by 90% between 2015 and 2035 [2]. Although there has
been a decrease in global TB incidence rates and mortality, the
present rate of such decline is insufficient to meet the 2035 goals
mainly due to several challenges such as the rise of multidrug-
resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB)
[2]. Treatment of M/XDR-TB is extremely difficult since it requires
more expensive drugs with a higher toxicity profile, during
a longer period (up to 24 months), resulting in patient noncom-
pliance and poorer outcomes. Therefore, there is a need to identify
new drugs and new combined therapies that are better tolerated
with the possibility to treat both drug-susceptible and drug-
resistant TB alike, faster and efficiently.
Over the years, it has become widely accepted that the overall
resistance of mycobacteria to any antimicrobial agent is due to
a synergy between intrinsic and genetic resistance [3,4]. Since no
horizontal transfer of resistance genes has been reported in
Mycobacterium tuberculosis, genetic drug resistance is mainly
acquired by spontaneous mutations in chromosomal genes that
cause modification or overproduction of the drug target, provide
the ability to inactivate drugs, or decrease the activation of the
drug into its active form [5,6]. InM. tuberculosis, intrinsic resistance
is a result of the interplay between the impermeable cell wall,
which limits drug uptake, and the activity of membrane proteins,
also known as efflux pumps, that transport a variety of substrates
from the interior to the exterior of the cell [3,4,7,8]. Several studies
have proposed that efflux activity emerges before the acquisition
ofmutations in drug target-coding genes. Overexpression of efflux
pumps in M. tuberculosis previously exposed to subinhibitory
concentrations of isoniazid and ethambutol resulted in a low-
level resistance phenotype, which allowed the bacteria to survive
in the presence of the antibiotic until the acquisition of mutations
in drug target genes that confer high-level resistance [9–12]. This
has also been hypothesized for the emergence of resistance to
bedaquiline, a recent anti-TB drug recommended for use in the
treatment of M/XDR-TB. It was demonstrated that mutations in
rv0678, a regulator of the MmpS5-MmpL5 efflux pump, might be
the first step in low-level resistance, followed by high-level resis-
tance due to atpE mutations [13].
This may reflect what occurs during a long-term therapy, as in
the case of TB, where an inappropriate therapy may result from
incorrect prescription, poor compliance by the patient and
inadequate drug supply and quality. An unsuitable treatment
can cause a sustained pressure of subinhibitory concentrations
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of an anti-TB drug that may cause increased efflux activity and
survival of a low/moderate-level resistant population fromwhich
results the selection and expansion of mutation based drug-
resistant M. tuberculosis variants – the evolution of resistance
arrow-of-time in mycobacteria [3,4].
Therefore, it is crucial to understand the mechanism(s) that
cause efflux-mediated resistance in order to find appropriate
ways to prevent it. The use of an efflux inhibitor as adjuvant to
therapy would help lower the frequency of mutant selection and,
thus, prevent the development of resistance. In addition, given the
urgency for new therapeutic regimens for the control of M/XDR-
TB, new drug discovery strategies are needed in order to find new
drugs or repurpose existing drugs, including efflux inhibitors, in
a cost-effective way. After a literature search in PubMed, covering
the studies published on efflux in M. tuberculosis up to
February 2020, this review will give a general overview of what
is currently known about the contribution of efflux pumps in drug
resistance inM. tuberculosis and how efflux inhibitors may help to
ensure the effectiveness of anti-TB drugs and prevent the emer-
gence of M/XDR-TB. Finally, we will present our experience and
recent findings in using a new drug discovery strategy to identify
new anti-TB drugs that may be used as efflux inhibitors.
2. Efflux pumps and drug resistance in
M. tuberculosis
Efflux pump systems are membrane proteins that are widespread
in many organisms, including Gram-positive and -negative bac-
teria and eukaryotes. These transporters are categorized in differ-
ent families according to their structural characteristics and energy
requirements: ATP-binding cassette (ABC) superfamily; the major
facilitator superfamily (MFS); the multidrug and toxic compound
extrusion (MATE) family; the small multidrug resistance (SMR)
family; the proteobacterial antimicrobial compound efflux (PACE)
superfamily; and the resistance nodulation division (RND) super-
family. The ABC superfamily are classified as primary transporters
since they use the hydrolysis of ATP as energy source, whereas the
other families of efflux pumps are defined as secondary transpor-
ters, because they use the proton (or sodium in the case of MATE
family) gradient [14–16]. The efflux pumps that have been asso-
ciated with drug resistance in M. tuberculosis are summarized in
Table 1.
The natural role of efflux pumps is to intervene in several
physiologic processes. For example, Rv1410c (P55) is involved in
the maintenance of normal growth characteristics and in the
oxidative stress response and Rv1258c is important for normal
growth kinetics and cell morphology and it appears to play
a relevant role in the stationary phase of growth [17–19]. Other
transporters like the mycobacterial membrane proteins large
(MmpL) are involved in the transport of lipids and promote cell
wall biosynthesis [20,21]. In particular, MmpL3 is involved in the
export of mycolates, one of the key components of the cell wall
and MmpL7 exports phthiocerol dimycocerosate, a lipid compo-
nent of the outer membrane [22–26]. In addition to their natural
role in the cell, most efflux pumps have the ability to transport
a diversity of unrelated compounds. For example, Mmr plays
a role in the resistance to tetraphenylphosphonium, ethidium
bromide, erythromycin, acriflavine, safranin O, pyronin Y and
cetyltrimethylammonium bromide and Rv1217c-Rv1218c has
been associated with the efflux of several compounds and resis-
tance to biarylpiperazines, bisanilinopyrimidines, novobiocins,
pyrazolones, pyridines and pyrroles [27–29].
However, in the last years, efflux pumps have become more
relevant due to their association with resistance to antimicrobials,
namely first-line anti-TB drugs. For example, Rv1410c, Rv2936 and
Rv0783 may be responsible for low-level resistance to rifampicin
and Rv1258c has been reported to confer rifampicin tolerance
during macrophage infection [18,19,30–32]. Recently, it was
demonstrated that point mutations in Rv1258c in clinical isolates
can confer clinically relevant drug resistance to pyrazinamide,
streptomycin and isoniazid [33]. Exposure of M. tuberculosis to
isoniazid caused overexpression of mmpL7 and mmr, the latter
also in the presence of ethambutol [22,34–36]. The doxorubicin-
resistance operon, drrABC, has also been implicated in resistance
to ethambutol [37]. In 2017, Zhang and collaborators identified
four putative efflux proteins in M. tuberculosis: Rv0191, Rv3756c,
Rv3008, and Rv1667c. They demonstrated that overexpression of
the genes coding for these proteins caused resistance to pyrazi-
namide that was reduced by efflux inhibitors [38].
Efflux pumps have been associated with resistance to all
classes of antibiotics, including drugs used in the treatment
of drug-resistant TB. The ABC transporter coded by the
Rv2686c-Rv2687c-Rv2688c operon is responsible for fluoro-
quinolone efflux, while DrrABC is involved in resistance to
several antibiotics, including tetracycline, erythromycin, nor-
floxacin, streptomycin and chloramphenicol [37,39]. Recently,
it was demonstrated that MDR-TB isolates showed increased
overexpression of drrA and drrB [40]. Rv0194 has been asso-
ciated with resistance to β-lactams, streptomycin, tetracy-
cline, chloramphenicol and vancomycin, while Rv1258c
mediates low-level resistance to tetracycline and aminoglyco-
sides [19,30,41,42]. Other transporters implicated in drug
resistance are Rv2477 (ofloxacin and streptomycin) and
Rv1473 (macrolides) [41,43]. The Rv2994 is a MFS efflux
pump that is associated with resistance to streptomycin
and fluoroquinolones [34]. The Rv2333c has been shown to
confer low-level resistance to tetracycline and spectinomycin,
whereas Rv1410c has been associated with resistance to
clofazimine [18,44]. Recently, MmpL5 was demonstrated to
be involved in the resistance to bedaquiline, clofazimine and
other antibiotics [45–49].
Article highlights
● Tuberculosis (TB) control faces many challenges, including the
increase of drug-resistant forms of Mycobacterium tuberculosis that
require new effective therapeutic regimens.
● Efflux pumps play a significant role in the development of drug
resistance in M. tuberculosis during treatment; efflux inhibitors
could prevent this outcome.
● Scientific evidence supports the use of efflux inhibitors as therapeutic
adjuvants to increase the effectiveness of anti-TB drugs.
● Drugs that target energy metabolism components may inhibit several
bacterial physiological processes, namely the activity of efflux pumps.
● Drug repurposing can accelerate drug discovery and make it cost
effective, by finding new uses for existing approved drugs. This can
be achieved by using an in silico approach.
● New cost-effective strategies to identify safer efflux inhibitors should
be implemented in drug discovery programs.
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Overall, the described studies have highlighted the contri-
bution of efflux pumps to the development of drug resistance
and reinforced the urgency to develop strategies that prevent
efflux-mediated resistance.
3. Efflux inhibitors as a strategy to prevent
efflux-mediated resistance in M. tuberculosis
In the last years, there has been an increased interest in
the search and development of compounds that act as
efflux inhibitors. The use of these compounds in combina-
tion with currently used anti-TB drugs has the potential to
increase the intracellular concentration of these drugs,
thus improving or restoring the activity of standard anti-
mycobacterials in resistant strains and reduce the duration
of the treatment. Moreover, efflux inhibitors could help
overcome M. tuberculosis intrinsic resistance to antibiotics
and prevent the emergence of mutations conferring drug
resistance.
Although some efflux inhibitors have been identified in
the last years (Table 2), most of them have only been studied
in vitro and ex vivo, few moved to in vivo animal studies, with
even fewer reports of their use for the clinical management
of M/XDR-TB patients under compassionate therapy regimens
[50,51]. The reason for the rare use of these compounds is
mainly due to concerns with toxicity, since these agents can
target both prokaryote and eukaryote transporters. In fact,
the clinical development of several efflux inhibitors had to be
put on hold due to toxicity problems [52]. In order to be
used for therapeutic purposes, an efflux inhibitor should
present limited toxicity to the host’s cells at the dosage
required to achieve an effect against the infectious agent.
A way to overcome this problem would be to use selective
inhibitors that specifically target efflux pumps that are not
present in human cells. A drug discovery strategy that could
help overcome this limitation is drug repurposing [53]. In
many cases, the pharmacokinetics and toxicity data are
already available for a repurposed drug, allowing it to follow
directly to pre-clinical testing and clinical trials, thus reducing
time, costs and risks. In fact, some compounds known to be
efflux inhibitors are repurposed drugs that were already
approved for the treatment of other diseases. These com-
pounds and others that demonstrated inhibitory activity
against M. tuberculosis efflux pumps are described in the
following sections.
3.1. Phenothiazines
The phenothiazines are antipsychotic drugs that have long
been known to have in vitro and in vivo antimycobacterial
activity. Chlorpromazine, the first antipsychotic drug devel-
oped, was found to have anti-TB activity in vitro. However,
the interest in chlorpromazine as a possible anti-TB agent
decreased due to the side-effects observed in patients [54].
Other phenothiazines were found to have anti-TB activity, but
thioridazine (TZ) was the most promising, presenting a dual
effect on M. tuberculosis: i) inhibition of the activity of efflux
pumps; and ii) enhancement of macrophage killing activity
through the inhibition of potassium and calcium channels,
causing pH decrease in the phagolysosome, activation of the
hydrolases and consequent killing of the mycobacteria [4,54–
57]. This fact is particularly important since pulmonary TB is
considered mainly an intracellular infection of the alveolar
macrophage. Despite these promising results, there are only
two reports of clinical management of patients with TZ to
date: in Argentina, XDR-TB patients were successfully treated
with the combination of TZ and other antibiotics and, in India,
where this drug has been used for compassionate purposes in
Table 1. List of efflux pumps associated with drug resistance in M. tuberculosis.
Transporter Family Efflux pump Drugs related References
ABC Rv0194 β-lactams, STR, TET, CHL, VAN [41]
Rv1217c-Rv1218c INH, RIF, AZI-533 (pyrrole), AZI-219 (pyrazolone) [27,96]
Rv1473 Macrolides [43]
Rv1667c PZA [38]
Rv2477 OFX, STR [41]
Rv2686c-Rv2687c-Rv2688c FQs [39]
Rv2936-Rv2937-Rv2938 (DrrABC) CHL, EMB, ERY, FQs, RIF, STR, TET [37]
Rv3756 PZA [38]
MFS Rv0191 CHL, EtBr, methylene blue, PZA [38.177]
Rv0783 INH, RIF [178]
Rv0849 AZI-533 (pyrrole), AMK [96]
Rv1258c (Tap) Aminoglycosides, AZI-533 (pyrrole), INH, OFX, PZA, RIF, STR, TET [30,33,42,96]
Rv1410c (P55) INH, EMB, RIF, CFZ [17,18]
Rv1634 FQs [179]
Rv2333c (Stp) SP, TET [44]
Rv2459 (JefA) INH, EMB [87]
Rv2846c (EfpA) INH, ETH [180,181]
Rv2994 STR, FQs, CIP [34]
Rv3008 PZA [38]
Rv3728 INH, EMB [34]
RND Rv2942 (MmpL7) INH [22]
Rv0676c-Rv0677c (MmpL5-MmpS5) BDQ, CFZ, azole [13,45-48,182]
SMR Rv3065 (Mmr) INH, EMB, EtBr, TPP, CTAB, AZI-533 (pyrrole) [28,29,35,36,96]
ABC, ATP-binding cassette; AMK, amikacin; BDQ, bedaquiline; CFZ, clofazimine; CHL, chloramphenicol; CIP, ciprofloxacin; CTAB, cetyl trimethylammonium bromide;
EMB, ethambutol; EtBr, ethidium bromide; ERY, erythromycin; ETH, ethionamide; FQs, fluoroquinolones; INH, isoniazid; MFS, major facilitator superfamily; OFX,
ofloxacin; PZA, pyrazinamide; RIF, rifampicin; RND, resistance nodulation division; SMR, small multidrug resistance; SP, spectinomycin; STR, streptomycin; TET,
tetracycline; TPP, tetraphenylphosphonium; VAN, vancomycin.
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the treatment of XDR-TB patients failing other treatment regi-
mens [50,51]. The reason is mainly due to concerns with
toxicity. Although very small concentrations of TZ are required
to kill the bacilli inside the macrophages, there is still the
concern of adverse side-effects in the central nervous system
and cardiotoxicity, which may occur over a prolonged admin-
istration period such as the one required for TB treatment.
Efforts have been made to reduce toxicity, such as the synth-
esis of TZ analogs or the encapsulation of the drug in nano-
particles, but further pre-clinical studies and clinical trials are
needed [58,59]. It has been suggested that TZ indirectly inhi-
bits efflux pumps or ion channels by blocking their energy
supply, ATP or proton motive force (PMF), required for sub-
strate transport. This is a result of the inhibition of the type-II
NADH menaquinone oxidoreductase (NDH-2), a key protein of
the oxidative phosphorylation pathway [60]. The importance
of this pathway as a novel target pathway for drug discovery
was recently supported by the development of bedaquiline,
which targets the mycobacterial ATP synthase, another oxida-
tive phosphorylation component [61]. Unfortunately, bedaqui-
line, which revealed to be highly potent against M/XDR-TB
strains in vivo and an excellent drug against all forms of
rifampicin resistant TB, also suffers from the same adverse
side-effects in the central nervous system and cardiotoxicity
reported for phenothiazines [62]. Therefore, given the demon-
strated potential of TZ and the scarcity of new drug targets for
TB, it is of extreme importance to further explore the drug’s
mode of action in order to identify potential targets for the
development of new and less toxic analogues.
3.2. Phenylalkylamines
Phenylalkylamines are calcium channel blockers and are often
used to treat various disorders, such as angina, hypertension
and cardiac arrhythmia. The classical example of this group is
verapamil (VP), which is also a substrate and inhibitor of the
mammalian drug efflux pump P-glycoprotein and of uptake
transporters such as the organic cation transporter protein
[63–65]. Over the years, several studies have demonstrated
that VP can strongly inhibit efflux of ethidium bromide in
mycobacteria [66,67]. In addition, VP was found to partially
restore the in vitro activity of rifampicin, isoniazid, ethambutol
and fluoroquinolones in drug-resistant M. tuberculosis isolates
[9,11,35,36,68–71]. Moreover, this compound also prevented
the acquisition of drug tolerance inside macrophages and
accelerated the sterilization of infected lungs in mice treated
with a first-line drug regimen [32,72]. In addition, co-
administration of VP with subinhibitory doses of bedaquiline
had the same bactericidal effect in mice as the bedaquiline
dose used in humans and also protected against the devel-
opment of resistant mutants in vivo [72]. Other studies
demonstrated that VP decreased the MIC of bedaquiline and
clofazimine in M. tuberculosis both in drug-susceptible and
drug-resistant clinical isolates [73,74]. Moreover, VP also
reduced macrophage-induced drug tolerance to bedaquiline
and moxifloxacin [75]. However, another study showed that
VP reduced the MIC of bedaquiline and clofazimine in vitro
but failed to increase the bactericidal effect of bedaquiline
in vivo [47]. Nevertheless, other studies described that VP
Table 2. List of most frequently used efflux inhibitors in M. tuberculosis.
Class/Origin Efflux inhibitor Mechanism of action Description/clinical use
Drugs with restored
activity in vitro Reference
Phenothiazines Chlorpromazine
Thioridazine
Inhibitors of K+ transport and Ca2+
channels
Inhibitor of NDH-2
Antipsychotics CLA, INH [55–57]
Phenylalkylamines Verapamil Ca2+ channel blocker
Interferes with membrane energetics








INH, RIF, OFX, STR [30,39,68]
Valinomycin Depletes the K+ electrochemical
gradient
K+ specific efflux inhibitor
High selectivity for Na+ and K+
Novobiocin, RIF [18]




INH, OFX, PZA [88–90]
Piperine Inhibits the human P-gp Plant alkaloid
Inhibitor of metabolism/transport of
metabolites and xenobiotics
RIF; STR [91,92]






Biochanin A Inhibits the human P-gp Natural compound (isoflavone) EtBr [94,183]
Luteolin Induces apoptosis in cancer cells Natural compound (flavone) EtBr [94,184]




Inhibitor of RND transporters
CFZ [96–99]
Timcodar Inhibitor of several mammalian efflux
pumps
Macrolide-derivative RIF, BDQ, CFZ, MXF [100,101]
UPAR-174 Glycolytic pathway enolase inhibitor 2-aminothiazole EtBr [102–104]
BDQ, bedaquiline; CCCP, carbonyl cyanide m-chlorophenyl hydrazone; CFZ, clofazimine; CLA; clarithromycin; DNP, 2,4-dinitrophenol; EtBr, ethidium bromide; INH,
isoniazid; MXF, moxifloxacin; NDH-2, type-II NADH menaquinone oxidoreductase; OFX, ofloxacin; PAβN, phenylalanine-arginine β-naphthylamide; P-gp, P-
glycoprotein; PMF, proton motive force; RIF, rifampicin; RND, resistance nodulation division; STR, streptomycin.
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increased the sterilizing activity of a regimen composed of
bedaquiline, clofazimine, and pyrazinamide in vivo, but had no
significant effect on bedaquiline pharmacokinetics [76,77].
Preclinical studies also indicate that VP potentiates the activity
of bedaquiline against M. tuberculosis, reducing the bedaqui-
line dose required for cure, which could be a promising strat-
egy for improving MDR-TB treatment [78–81]. In addition, VP
may be cardioprotective, reducing the risk of QT prolongation
and the dose related toxicity [78]. However, the effect of VP
in vivo is probably due to a higher bioavailability of the co-
administered drugs through an effect on the mammalian drug
transporters, rather than by the inhibition of mycobacterial
efflux pumps [76,82–84]. Recently, it has been shown that VP
does not affect intracellular drug uptake in M. tuberculosis
through direct inhibition of efflux pumps, but it indirectly
alters efflux pump function by interfering with membrane
energetics [85]. Nevertheless, VP concentrations required to
achieve bactericidal activity against M. tuberculosis are very
high and likely to be toxic to human cells. Therefore, further
studies are needed to design more effective and selective VP
analogs.
3.3. Protonophores
These compounds, also known as proton translocators or
uncouplers, dissipate the PMF and electrochemical gradient,
preventing further synthesis of ATP and, consequently, the
normal function of cell processes that depend on this energy
gradient such as efflux pumps [4,56,86]. Carbonyl
cyanide m-chlorophenyl hydrazone (CCCP), 2,4-dinitrofenol
(DNP) and valinomycin are examples of such compounds
that have been widely used to study the role of efflux
pumps in mycobacteria. For example, CCCP decreased the
MIC of tetracycline in a M. smegmatis strain expressing
Rv1258c and decreased the activity of this efflux pump in
a M. bovis BCG overexpressing strain [19,30]. Moreover, CCCP
was one of the efflux inhibitors that abolished the decreased
susceptibility to several compounds, such as ethidium bro-
mide, acriflavine and safranin O in M. tuberculosis strains over-
expressing jefA and mmr (Rv3065) (Rv2459) [28,87]. CCCP and
valinomycin reduced novobiocin and rifampicin resistance
mediated by P55 [18]. It was also demonstrated in several
studies that CCCP and DNP reduce efflux pump activity asso-
ciated with fluoroquinolone resistance [39,68,87]. However,
due to their mechanism of action, these compounds are highly
cytotoxic and, thus, further studies are needed to determine
the concentrations that are simultaneously the safest and
most effective.
3.4. Plant-derived compounds
In the last years, several efflux inhibitors of plant origin have
been described. Reserpine, piperine, farnesol, luteolin and
biochanin A are among the most used in M. tuberculosis. The
alkaloid reserpine was used for many years as an antihyper-
tensive, but its toxicity limited its clinical use [56,86].
Nevertheless, this compound has been widely used in the
in vitro evaluation of the activity of antimicrobial agents,
namely in mycobacteria. For example, reserpine reduced
ciprofloxacin resistance mediated by Rv2686 and decreased
the MIC of isoniazid in M. smegmatis expressing mmpL7
[22,39]. In addition, reserpine increased susceptibility to iso-
niazid in M. bovis BCG and in M. tuberculosis susceptible and
resistant strains [88,89]. This compound has also been shown
to inhibit the pyrazinoic acid efflux pump, thus, increasing
susceptibility to pyrazinamide in M. tuberculosis [90].
Piperine, an organic alkaloid compound found in Piper
nigrum and Piper longum, was reported to inhibit the
Rv1258c efflux pump in M. tuberculosis [91]. Recently, it was
demonstrated that piperine had a synergistic effect with rifam-
picin and streptomycin, but low effect in enhancing the killing
in several strains of M. tuberculosis with different resistance
profiles [92]. Therefore, further studies are needed to clarify if
piperine may be used as an adjunctive drug in TB treatment.
Other natural products such as farnesol, biochanin A and
luteolin have been shown to inhibit efflux of ethidium bro-
mide in M. smegmatis [93,94]. Recently, modified biochanin
A derivatives inhibited efficiently M. avium efflux pumps in
a synergistic activity with macrolides and fluoroquino-
lones [95].
3.5. Other efflux inhibitors
Other compounds with efflux inhibitor activity are Phe-Arg-β-
naphtylamide (PAβN) and timcodar. PaβN is known to be
a broad-spectrum efflux inhibitor of several Gram-negative
bacteria and was reported to be active against
M. tuberculosis [96–98]. However, there have been evidences
that PaβN may not be the most adequate tool to study efflux
mechanisms since it is also an efflux pump substrate and
presents a dual mode of action: efflux inhibition and mem-
brane-permeabilizing activity [97–99].
Timcodar is a mammalian efflux pump inhibitor that
showed synergism when used in combination with rifampicin,
bedaquiline and clofazimine [100]. When assessing the activity
of this compound against intracellular M. tuberculosis in host
macrophages, it was demonstrated that timcodar caused
approximately a 10-fold increase in the growth inhibition of
M. tuberculosis and presented synergy with rifampicin, moxi-
floxacin and bedaquiline [100]. Moreover, in a mouse model of
infection, timcodar potentiated the efficacy of rifampicin and
isoniazid. However, no additive effect of timcodar was
observed when used in combination with moxifloxacin and
linezolid [100,101]. Therefore, further studies are required to
evaluate the effect of timcodar in the potentiation of efficacy
of anti-TB drugs.
In order to potentiate the activity at lower concentrations
and decrease the associated toxicity of efflux inhibitors target-
ing energy in M. tuberculosis, lipophilic compounds that pre-
sent concomitant anti-TB and efflux inhibitory activity were
designed. This is the case of the very promising 2-aminothia-
zole UPAR-174, a glycolytic pathway enolase inhibitor that also
acts as efflux inhibitor, active against replicating, nonreplicat-
ing and intracellular M. tuberculosis, dissipating membrane
potential and causing ATP depletion [102–104].
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4. An in silico repurposing strategy to identify
potential efflux inhibitors in M. tuberculosis
Overall, themajority of the knownmycobacterial efflux inhibitors
are derived from existing drugs developed for other therapeutic
usages that revealed high efflux inhibitory activity in vitro. These
compounds are good examples of a rational approach that
accelerates drug discovery and makes it cost effective – drug
repositioning or repurposing [53]. It has been observed that the
most effective ones are those that have a direct effect on the
mycobacterial energy metabolism [86,103,105]. Energy metabo-
lism and limiting ATP production, as well as the PMF balance, are
the most efficient ways to inhibit mycobacterial efflux and are
critical for antibiotic susceptibility of M. tuberculosis [105].
As previously mentioned, the oxidative phosphorylation path-
way has emerged as a novel target pathway for TB drug discovery,
due to the development of bedaquiline, which targets the myco-
bacterial ATP synthase [61]. The inhibition of the different compo-
nents of this pathway prevents respiratory electron transport,
abolishes the PMF and stops production of ATP, thus inactivating
several physiological processes including the activity of efflux
pumps and ion channels active transport [106]. An example of
this is TZ, the antipsychotic drug that indirectly inhibits efflux
pumps or ion channels as a result of the inhibition of NDH-2 that
intervenes in the oxidative phosphorylation pathway [57,60].
Considering the above premises, compounds that block the oxi-
dative phosphorylation pathway may have a similar activity or
even surpass the potential of TZ. Therefore, it is of great impor-
tance to explore oxidative phosphorylation as a target for the
development of new drugs against TB. In the following subsec-
tions, we describe and review the basis of a new strategy for the
identification of drugs with potential inhibitory activity against
efflux pumps inM. tuberculosis – a target-based approach directed
to proteins involved in energy metabolism and membrane trans-
port in M. tuberculosis, based upon in silico drug repurposing.
4.1. Generation of an in silico library of approved drugs
with potential activity against M. tuberculosis
The rational workflow of the strategy is summarized in Figure 1
and is inspired in the methodology previously described by
Bispo et al. and Neves et al. and can be easily adapted to other
metabolic pathways and other microorganisms [107,108]. A list
of M. tuberculosis proteins involved in energy metabolism and
membrane transport was compiled using the TDR Targets
Database and Mycobrowser [109,110]. In the case of TDR
Targets Database the strategy was as follows: i) Enter TDR targets
database, http://www.tdrtargets.org/, select targets [111]; ii)
Select M. tuberculosis; iii) Targets: Select ‘energy metabolism’,
‘oxidative phosphorylation’ and ‘membrane transport’ under
the parameter ‘KEGG high-level pathway’. The search results
obtained with TDR targets were crosschecked and complemen-
ted with a search in Mycobrowser: i) Enter Mycobrowser website
https://mycobrowser.epfl.ch/ [112]; select Advanced Search;
Enter protein function and free text search: ‘energy’, ‘oxidative
phosphorylation’, ‘membrane’, ‘transporter’. This search revealed
668 genes that encode proteins involved in energy metabolism
and membrane transport (Table S1). The corresponding protein
sequences were used to interrogate two publicly available web-
based databases that provide detailed information on drugs and
their targets: DrugBank and STITCH 5.0 [113,114]. The search
strategy used by DrugBank relies on the principle of homology,
where each query (query = protein of M. tuberculosis) results in
a comparison by similarity with all drug targets known to the
databases. Only proteins with a statistical similarity value of
E-value ≤ 10−20 were considered potential targets [108]. STITCH
defines a group of interactions of variable statistical confidence
between drugs and targets. In this case, only targets with a score
≥ 0.8 were considered for further studies [108]. From the targets
selected from both databases only the ones predicted to interact
with approved drugs were selected. The sequence similarity
screening in these databases predicted 69 targets associated
with 246 approved drugs. Examples of the protein targets and
their respective functions are presented in Table 3 (the complete
data can be found in Table S2). DrugBank and STITCH 5.0 exclu-
sively predicted 216 (87.8%) and 12 (4.9%) of the approved
drugs, respectively, whilst 18 (7.3%) drugs were predicted by
both databases. The functional regions of the approved drug
targets and M. tuberculosis targets were compared using The
ConSurf Server, a bioinformatics tool for estimating the evolu-
tionary conservation of amino acid positions in a protein based
on the phylogenetic relationships between homologous
Figure 1. Flowchart summarizing the in silico drug repurposing strategy and corresponding results.
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sequences [115]. This procedure was used to estimate the con-
servation of active sites between the proteins and the preserva-
tion of affinity for the predicted M. tuberculosis drugs. The
parameters for the analysis were selected as previously described
[108]. The results obtained were classified as functional residues
with high (≥ 80%) or moderate conservation (60-79%). When the
conservation between functional residues is less than 59%, the
putative targets were excluded from further analyzes. This strat-
egy resulted in a list of 19 potential druggable M. tuberculosis
targets (2.8% of the interrogated targets) that could interact with
24 approved drugs. Table 3 presents these targets and their
potential drugs (detailed data provided by Table S2). These
drugs are approved for a variety of indications, such as treatment
of epilepsy, chronic immune thrombocytopenia, arrhythmia and
cancer (Figure 2). The PubMed database was used to verify if the
identified drugs had already been tested against M. tuberculosis
[116]. Drugs were classified as ‘tested’ when any in vitro and/or
in vivo tests were already performed in M. tuberculosis and ‘not
tested’ when no publication could be found. According to this
search, the following drugs were never tested against
M. tuberculosis: acetyldigitoxin, bretylium, deslanoside, dexlanso-
prazole, enasidenib, esomeprazole, ethacrynic acid, fomepizole,
halothane, isoflurane, ivosidenib, levoleucovorin, rabeprazole
and tipiracil.
4.2. Drugs already tested against M. tuberculosis
From the 24 drugs identified using this strategy, 10 were
already tested for activity against M. tuberculosis. As proof-of-
concept, this strategy successfully identified bedaquiline,
recommended by WHO as part of combination therapy in
adults with pulmonary MDR-TB [117]. Since bedaquiline tar-
gets the mycobacterial ATP synthase, an enzyme that inter-
venes in the oxidative phosphorylation and essential for the
generation of energy in M. tuberculosis, this provides an ade-
quate validation of the strategy.
Doxorubicin was also one of the drugs identified by this
method. This drug is an antineoplastic in the anthracycline
class, used to produce regression in solid tumors and dissemi-
nated neoplastic conditions and as a component of adjuvant
chemotherapy in breast cancer. However, doxorubicin can
cause toxicity in multiple organs, including cardiotoxicity,
which has to do with its mechanism of action [118,119].
Doxorubicin binds to nucleic acids, presumably by specific
intercalation of the planar anthracycline nucleus with the
DNA double helix. It may also inhibit polymerase activity,
affecting regulation of gene expression, and producing free
radical damage to DNA [120]. In mycobacteria, previous stu-
dies have found evidences that doxorubicin is a potent inhi-
bitor of the DNA primase (DnaG), with an MIC of 5 μM in
M. tuberculosis [121]. Our analysis revealed the NADH dehy-
drogenase I chain B (Rv3146) and chain D (Rv3148) as poten-
tial targets of doxorubicin in M. tuberculosis. However, it has
been previously demonstrated that doxorubicin is a substrate
of efflux pumps, particularly the DrrAB transporter, which
undermines its potential as anti-TB drug [37]. Therefore,
further studies are necessary in order to clarify the mode of
action of doxorubicin in M. tuberculosis and to develop safer
derivatives that are not subject to efflux.
Fostamatinib is indicated for the treatment of rheumatoid
arthritis, chronic thrombocytopenia and autoimmune diseases
and acts as an inhibitor of the tyrosine kinase. Fostamatinib is
a pro-drug, requiring hydrolysis by the intestine’s alkaline
phosphatase that generates R406, which is the active metabo-
lite [122]. Neither fostamatinib nor R406 were found to be
carcinogenic or mutagenic. Serious adverse effects include
hypertension, neutropenia, diarrhea, and hepatotoxicity in
the recommended human dose [123–125]. In 2018, Kanehiro
et al. described R406 as an inhibitor of the mycobacterial
serine/threonine-protein kinase PknG. The same study demon-
strated that R406 showed bactericidal activity against M. bovis
BCG in infected human macrophages without cytotoxicity
[126]. Fostamatinib was revealed by our in silico method to
have several potential targets in M. tuberculosis: transmem-
brane serine/threonine-protein kinase B (Rv0014c); transmem-
brane serine/threonine-protein kinase A PknA (Rv0015c);
probable transmembrane serine/threonine-protein kinase
E PknE (Rv1743) and anchored-membrane serine/threonine-
protein kinase PknF (Rv1746). Interestingly, Rv0014c and
Rv0015c are essential genes.
Thiabendazole is a fungicide and parasiticide mostly used for
the treatment of strongyloidiasis, cutaneous larva migrans, visc-
eral larva migrans, and trichinosis. Thiabendazole is a known
inhibitor of tubulin polymerization. It selectively binds to nema-
tode ß-tubulin, inhibiting polymerization, thus preventing the
formation of microtubules and preventing cell division [127,128].
Thiabendazole has also been shown to inhibit the helminth-
specific enzyme, fumarate reductase [129]. Previous studies
examined the effect of thiabendazole in M. tuberculosis and
demonstrated that this drug prevented FtsZ polymerization,
causing septum formation inhibition and, thus, abolishing cell
division [130,131]. Our strategy identified a probable succinate
dehydrogenase (Rv0248c) and a probable fumarate reductase
(Rv1552) as potential targets of thiabendazole in M. tuberculosis.
These enzymes are involved in interconversion of fumarate and
succinate in aerobic respiration. Experimental studies are now
needed in order to determine if these proteins are indeed targets
of thiabendazole.
Valproic acid, or valproate, is a fatty acid derivative and
anticonvulsant used in the treatment of epilepsy and bipolar
disorders [132]. This drug has been also investigated for neu-
roprotective, anti-manic, and anti-migraine effects. Currently, it
is a compound of interest in oncology drug research for its
anti-proliferative effects and is the subject of many clinical
trials. The mechanism of action of valproate is relatively
unknown, but it is suggested that the drug’s action is
a result of several pathways: i) inhibition of succinic semialde-
hyde dehydrogenase and increasing GABAergic neurotrans-
mission; impact on fatty acid metabolism, which alters
membrane fluidity; and noncompetitive inhibition of brain
microsomal long-chain fatty acyl-CoA synthetase, which
decreases available arichidonyl-CoA, a substrate in the produc-
tion of inflammatory prostaglandins [133–135]. Valproate has
been previously tested in M. tuberculosis. In 2015, Schieber
et al. demonstrated that this drug stimulates the autophago-
some formation in vitro and, in 2018, Rao and collaborators
showed that it improves the action of isoniazid and rifampicin
in the macrophage [136,137]. However, the specific target in
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M. tuberculosis has not been identified to date. Our study
predicted a possible acyl-CoA dehydrogenase FadE19
(Rv2500c) as a potential M. tuberculosis target.
Ouabain is a cardiac glycoside similar to digitoxin that is
used to treat congestive heart failure, supraventricular arrhyth-
mias and to control ventricular rate in the treatment of chronic
atrial fibrillation [138,139]. This compound inhibits the Na+/K+-
ATPase membrane transporter, causing an increase in intracel-
lular sodium and calcium concentrations, which may promote
activation of contractile proteins such as actin and myosin
[140]. Ouabain has been demonstrated to potentiate the intra-
cellular killing of M. tuberculosis by macrophages [141,142].
Recently, Kaur and collaborators performed a virtual screening
to search for novel drugs against secretory lipid-catabolizing
enzymes in M. tuberculosis. Ouabain was identified as
a suitable drug for the enzyme LipU [143]. We have predicted
a probable metal cation transporter P-type ATPase A (Rv1997)
as a possible target for ouabain. These evidences suggest that
this compound affects several cell processes and, thus, more
studies are needed to clarify its mode of action.
Metformin is an antihyperglycemic agent used for themanage-
ment of type II diabetes and is prescribed to at least 120 million
people worldwide [144,145]. It is suggested that metformin inhi-
bits the mitochondrial complex I, preventing the production of
mitochondrial ATP leading to increased cytoplasmic ADP:ATP and
AMP:ATP ratios. These changes activate the AMP-activated protein
kinase, an enzyme that plays an important role in the regulation of
glucose metabolism [146,147]. Our analysis identified Rv0235c,
annotated as a probable conserved transmembrane protein
involved in cell wall and cell processes, as a potential target for
metformin in M. tuberculosis. However, this drug has been the
subject of several studies evaluating the use of metformin in TB
treatment. It was demonstrated that the use of metformin in
diabetes mellitus patients reduced the risk of subsequent active
TB and that it has potentially beneficial effects in innate host
responses to M. tuberculosis [148,149]. A study using the mouse
model of TB infection found thatmice treatedwithmetformin and
isoniazid showed a considerable reduction in the bacillary load in
the lungs and reduced areas of lung tissue damage compared
with isoniazid monotherapy [150,151]. A clinical trial is being
conducted to assess the efficacy and safety of metformin-
containing anti-TB treatment in comparison to the standard
6-month regimen in patients with newly diagnosed sputum
smear-positive drug-sensitive pulmonary TB [152].
Our in silico strategy also identified several compounds used to
treat gastric acid-related disorders. They are known to be inhibi-
tors of the parietal gastric cell H+/K+-ATPase pump, hence their use
in gastroesophageal reflux disease, peptic ulcer disease, and other
diseases characterized by the oversecretion of gastric acid. Our
analysis predicted a probable metal cation transporter P-type
ATPase A CtpF (Rv1997) as a potential target in M. tuberculosis. In
the case of omeprazole and pantoprazole, a previous study has
revealed that these drugs have no effect in M. tuberculosis [153].
On the other hand, the same study showed that lansoprazole has
intracellular activity against M. tuberculosis. Target identification
studies revealed that lansoprazole killsM. tuberculosis by targeting
its cytochrome bc1 complex leading to disruption of the myco-
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The described body of work already performed, provide
useful data about the identified drugs that may be used as
a starting point for future studies by the scientific and phar-
maceutical community. In this case, information concerning
toxicity and pharmacokinetics properties will have to be con-
sidered before selecting the most promising compounds.
4.3. Drugs not yet tested against M. tuberculosis
We predicted 14 drugs that, to our knowledge, have not yet
been experimentally tested against M. tuberculosis.
Levoleucovorin is indicated for use as rescue therapy following
high-dose methotrexate in the treatment of osteosarcoma or
for diminishing the toxicity associated with inadvertent over-
dosage of folic acid antagonists. Levoleucovorin has an addi-
tional indication for use in combination chemotherapy with
5-fluorouracil in the palliative treatment of patients with
advanced metastatic colorectal cancer [154,155]. The pre-
dicted M. tuberculosis target is the serine hydroxymethyltrans-
ferase GlyA2 (Rv0070c).
Our study identified two drugs that are used for the treatment
of adult patients with relapsed or refractory acute myeloid leuke-
mia, ivosidenib and enasidenib. These agents are inhibitors of
isocitrate dehydrogenases 1 and 2, mitochondria-localized
enzymes involved in diverse cellular processes [156–158]. The
potential M. tuberculosis target identified in this study for both
drugs is a probable isocitrate dehydrogenase (Rv3339c).
Tipiracil is a thymidine phosphorylase inhibitor that is used
in combination with trifluridine for the treatment of refractory
metastatic colorectal cancer [159]. The predicted target in
M. tuberculosis is the thymidine phosphorylase DeoA
(Rv3314c).
Dexlansoprazole, esomeprazole and rabeprazole are inhibi-
tors of the human H+/K+-ATPase, that to our knowledge have
not been tested in M. tuberculosis. The predicted target iden-
tified by our method is a probable metal cation transporter
P-type ATPase A CtpF (Rv1997). Further studies are needed to
evaluate the effect of these compounds in M. tuberculosis.
However, the adverse effect of these drugs needs to be further
clarified due to recent evidence that prescription of acid-
suppressive agents seems to be associated with TB infection/
activation [160,161].
This strategy also identified several antiarrhythmic, antihyper-
tensive drugs that potentially target a probable metal cation
transporter P-type ATPase A CtpF (Rv1997) in M. tuberculosis.
Deslanoside is a cardiac glycoside used to treat congestive
heart failure, supraventricular arrhythmias and to control ventri-
cular rate in the treatment of chronic atrial fibrillation. This
compound inhibits the Na+/K+-ATPase pump, resulting in an
increase in intracellular sodium and calcium concentrations
that may promote activation of contractile proteins, such as
actin and myosin [162]. Acetyldigitoxin is a cardioactive deriva-
tive of lanatoside A or of digitoxin used for fast digitalization in
congestive heart failure. The proposed mode of action is similar
to deslanoside: inhibition of the Na+/K+ pump that leads to
increased amounts of calcium [163]. Ethacrynic acid is used in
the treatment of high blood pressure and edema caused by
diseases like congestive heart failure, liver failure, and kidney
failure. It inhibits the symport of sodium, potassium, and chloride
primarily in the ascending limb of Henle. This pharmacological
action results in excretion of these ions, increased urinary output,
and reduction in extracellular fluid [164]. Finally, the last drug in
this group is bretylium, used in emergency medicine, cardiology,
and other specialties for the acute management of ventricular
tachycardia and ventricular fibrillation. The main mode of action
for bretylium is thought to be inhibition of voltage-gated potas-
sium channels and the Na+/K+-ATPase [165].
Fomepizole is used as an antidote in confirmed or sus-
pected methanol or ethylene glycol poisoning. It is
a competitive inhibitor of alcohol dehydrogenase, the enzyme
that catalyzes the initial steps in the metabolism of ethylene
glycol and methanol to their toxic metabolites [166]. The
predicted target in M. tuberculosis is the zinc-type alcohol
dehydrogenase AdhD (Rv3086).
Halothane and isoflurane are general inhalation anesthetics
used for induction and maintenance of general anesthesia
[167]. Halothane causes general anesthesia due to its actions
on multiple ion channels, which ultimately lowers nerve
Figure 2. Distribution of the predicted drugs according to their original indication.
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conduction, breathing and cardiac contractility. Its immobiliz-
ing effects have been attributed to its binding to potassium
channels in cholinergic neurons [168]. Isoflurane’s anesthetic
effect is thought to be the result of: i) the reduction in junc-
tional conductance by decreasing gap junction channel open-
ing times and increasing gap junction channel closing times;
ii) the activation of calcium dependent ATPase in the sarco-
plasmic reticulum by increasing the fluidity of the lipid mem-
brane; iii) the binding to the D subunit of ATP synthase and
NADH dehydrogenase; iv) the binding to the GABA receptor,
the large conductance calcium-activated potassium channel,
the glutamate receptor and the glycine receptor [169]. The
potential M. tuberculosis target identified in this study is
a probable NADH dehydrogenase I (chain H) (Rv3152). We
did not find any published study of these agents as antimy-
cobacterials and little is known about the antibacterial
mechanisms of anesthetics, with previous studies reporting
contradictory results [170–172]. The technical difficulties asso-
ciated with the study of these agents may be responsible for
the variety of results obtained.
Experimental evidence is needed to clarify if any of these
identified drugs presents antimycobacterial activity and if their
mechanism of action involves the suggested targets. In addi-
tion, it is also imperative to determine if their absorption,
distribution, metabolism, excretion and toxicity (ADMET) prop-
erties could affect their activity in vivo. If their activity is
revealed to be promising, these compounds could be impor-
tant leads in TB drug discovery.
4.4. Experimental strategies for validation of activity of
identified drugs
To confirm the efficacy of these drugs, in vitro and in vivo
studies will have to be performed. This can be applied even to
the drugs that have already been tested against
M. tuberculosis, since these compounds may be interesting
lead molecules and become the starting point for the design
of new improved molecules. The identified drugs will need to
be sequentially evaluated using different methodologies in
order to be classified as potential antimycobacterials or as
potential efflux inhibitors [35,36,55,173]. However, this classi-
fication may be confusing as the same compound can be
a good efflux inhibitor and restore the activity of established
antibiotics, while presenting antimicrobial activity by itself at
concentrations near its MIC. Determination of MICs in vitro in
extracellular (bacteria in liquid culture) and intracellular con-
ditions (infected macrophages) will give information concern-
ing the activity of these compounds against M. tuberculosis
and their ability to enhance the killing of intracellular myco-
bacteria. In addition, the evaluation of synergistic interactions
between these drugs and currently used anti-TB drugs (e.g.
checkerboard method) will allow the identification of potential
adjuvants. In this case, further studies would have to be
performed in order to clarify if a given compound acts as
adjuvant by inhibition of efflux or by other mechanism(s).
Efflux activity can be studied using a fluorescent marker dye,
such as ethidium bromide, as an efflux pump substrate in
several bacteria [35,36,66,67]. In addition to the assays
described above, the predicted target on M. tuberculosis
must be confirmed, for example, through the selection of
resistant mutants in the presence of the compound or by
the construction of knockdown and overexpression mutants
and the following comparison of the MIC of these strains with
the wild-type strain. However, even if a given drug proves
itself to be promising after these studies, the issue of toxicity
must be addressed. Therefore, evaluation of drug cytotoxicity
in specific cell-lines (e.g., human macrophages and others)
must be carried out in parallel with the determination of
antimycobacterial activity. Only the compounds that can be
used at safe concentrations should be selected. Other studies
could also involve the determination of in vitro and ex vivo
drug activity against drug-susceptible and M/XDR-TB
M. tuberculosis strains. Furthermore, efficient penetration
through the lipidic mycobacterial cell wall of new anti-TB
drugs must be guaranteed and lipophilicity is a very important
feature to consider in designing new or repurposing old drugs
as effective agents against M. tuberculosis [103]. Finally, the
compounds that prove to be the most interesting, with the
desired antimycobacterial and synergistic properties, as well as
demonstrable inhibitory activity at low nontoxic concentra-
tions, will be selected for further research, namely in the
mouse model and pharmacokinetic and pharmacodynamic
studies in preparation for potential clinical trials [36,58,173].
5. Conclusion
It is now widely accepted and demonstrated that mycobacter-
ial efflux pumps contribute to drug resistance by allowing the
bacteria to survive in the presence of subinhibitory concentra-
tions of antibiotics until the emergence of mutations, as
reviewed in this work. Several evidences support the use of
efflux inhibitors as a strategy to overcome efflux of anti-TB
drugs in mycobacteria, shortening the treatment regimens
and preventing the emergence of resistance, as aimed by
the WHO End TB Strategy [2,174]. In addition, several of
these efflux inhibitors also act as enhancers of the macro-
phage activity, which makes them especially useful in the
case of TB, since the bacteria reside inside the pulmonary
macrophage [4]. However, despite their promising results
in vitro, none of them have been used in clinical practice for
TB management, with the exception of TZ used in compassio-
nate therapy for particular XDR-TB cases [50,51]. Their applica-
tion in vivo is restricted mostly due to toxicity concerns, since
most of these compounds are able to target both prokaryote
and eukaryote transporters. In a time when new drugs are
needed to fight M/XDR-TB, cost-effective strategies to identify
safer efflux inhibitors should be implemented in drug discov-
ery programs. This review has highlighted a new strategy for
the development of anti-TB drugs, including efflux inhibitors,
using in silico drug repurposing (Figure 3). This approach has
been successfully used for the identification of new hits for
malaria, schistosomiasis, human african trypanosomiasis and
leishmaniasis [107,108,175]. Concerning the identified poten-
tial anti-TB drugs, if promising activities are revealed, they
could constitute important starting points for lead identifica-
tion and optimization and, ultimately, for the development of
new antimycobacterials, including efflux inhibitors.
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In conclusion, it is scientifically evident that efflux inhibitors
should be exploited for synergistic use with current therapeu-
tic regimens to improve the efficacy of TB treatment. If efflux
inhibitors can be used as adjuvants of currently used anti-TB
drugs, they could not only restore the activity of such drugs,
but also modulate the killing activity of the infected macro-
phage. However, there is still the need for clinical trials that
indisputably demonstrate the importance of efflux inhibitors
as adjuvant compounds for the current recommended thera-
pies for TB and M/XDR-TB. Several efforts have been made to
address specific issues such as toxicity, lipophilicity and selec-
tivity of these compounds. The synthesis of analogues of
known efflux inhibitors (e.g. VP and TZ analogues), the study
of certain natural derived products (e.g. berberine, piperine
and other berberflavonoids) and promising drug repurposing
strategies are important directions for the future development
of the ideal efflux inhibitor [92,103,104,176].
6. Expert opinion
TB is one of the top ten causes of death and the leading cause
from a single infectious agent (above HIV/AIDS). M. tuberculosis
has the ability to acquire resistance to all anti-TB drugs known,
leaving very limited therapeutic options. In order to prevent the
selection of resistant variants of M. tuberculosis, TB treatment
consists of a combination of three or more drugs, given simulta-
neously for a long period of time to promote their synergistic
activity and increase the probability of a successful outcome.
M. tuberculosis is equipped with other drug resistance mechan-
isms that act in synergy with drug resistance mutations, namely
efflux pump systems that allow the bacteria to survive in the
presence of subinhibitory concentrations of antibiotics until the
selection of resistant mutants. This fact is particularly relevant in
the case of TB, due to its long-term therapeutic regimens that
frequently cause poor patient adherence facilitating acquisition
of resistance. The inhibition of efflux pumps through the action
of efflux inhibitors could be a way to restore the activity of
antibiotics subject to efflux by decreasing the mutation fre-
quency and, thus, prevent the evolution toward resistance.
Therefore, efflux pumps are attractive drug targets and efflux
inhibitors could be used in combination with current anti-TB
drugs, in new therapeutic regimens, to help increase treatment
efficacy. The major limitation to this approach has to do with
toxicity, since most of these compounds have an effect on both
prokaryotic and eukaryotic cells. In particular, their side effects
could be an issue in combined therapy, emphasizing the need
for more advanced studies concerning the dose of efflux inhibi-
tor used in combination with existing first-line anti-TB drugs and
the subsequent side effects. It is crucial to tailor the pharmaco-
kinetics of the efflux inhibitor to the pharmacokinetics of the
antibiotic in order to optimize synergy. This applies even to drugs
that are already approved for clinical use for other diseases (e.g.
TZ and VP and analogues), which have shown promising in vitro
and in vivo activity against TB. Although the use of efflux inhibi-
tors as adjuvant therapeutic agents still faces many challenges,
the evidences show that they provide many advantages. Future
studies should continue to focus on the design and development
of new efflux inhibitors and new anti-TB drugs to be used in
combination of multiple drugs in new therapeutic regimens. In
this case, drug repurposing provides several advantages, namely
reducing costs, risk and time associated with drug discovery. This
approach combined with in silico computer-aided drug design
strategies can greatly improve the drug discovery paradigm and
help identify promising drug leads for TB. Also, new drugs and
drug development pipelines should always take into account the
effluxability of the drug as an important variable in its pharma-
codynamics and possible mechanism of resistance, as recently
happened with bedaquiline, and design strategies to minimize
these undesirable events that reduce tremendously its efficacy
and lifetime [13,47].
Figure 3. Graphical summary of the proposed strategy for the development of anti-TB drugs, using in silico drug repurposing. TB, tuberculosis.
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Ending the TB epidemic by 2030 is one of the health targets of
the UN Sustainable Development Goals (UN-SDGs). Therefore, it is
expected that many efforts will continue to be made in the next
five years in order to achieve this goal. This includes the design of
novel antimycobacterial agents and the development of acceler-
ated drug discovery strategies. Efflux inhibitors provide the attrac-
tive possibility of restoring the activity of already available
antibiotics, saving time, effort and financial investment that is
usually required for drug development. There is still a long way
to go before efflux inhibitors can be routinely used in clinical
practice. Future studies will continue to address the issues of
selectivity and safe usage of these compounds. Hopefully,
advancements in in silico and computer-aided drug design strate-
gies will help to achieve the rapid discovery of novel, effective and
safe efflux inhibitors drugs and ultimately decrease the global
burden of TB and contribute to achieve the 2030 UN-SDGs.
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